United Therapeutics(US:UTHR)2025-10-29 13:00Financial Performance - Total revenue reached $800 million, representing a 7% year-over-year increase compared to Q3 2024[30] - Tyvaso DPI and nebulized Tyvaso combined revenue increased by 10% year-over-year to $478 million[30, 58] - Orenitram revenue increased by 16% year-over-year to $131 million[30, 58] - Remodulin revenue decreased slightly by 2% year-over-year to $126 million[30, 58] - Unituxin revenue decreased by 22% year-over-year to $48 million[30, 58] - The company's trailing twelve months (TTM) operating cash flow is $16 billion, and it holds $43 billion in cash, cash equivalents, and marketable investments[31] Pipeline Development - TETON-2 study of nebulized Tyvaso for Idiopathic Pulmonary Fibrosis (IPF) met its primary endpoint[37] - TETON-1 study data for Tyvaso in IPF in the U S and Canada is expected in the first half of 2026[37, 40, 42] - The ADVANCE OUTCOMES study of Ralinepag for Pulmonary Arterial Hypertension (PAH) is fully enrolled with 728 patients, and data is expected in the first half of 2026[47, 50]